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并进一步探索巴茱合剂治疗 AD 的相关分子生物学机制。 
方法：（1）选取新型 APP/PS1 转基因小鼠(5xFAD 小鼠)作为实验对象。将 3
月龄 5xFAD 小鼠随机分为模型组 (5xFAD-Control)、巴茱合剂低剂量组
(5xFAD-BZD-L)、中剂量组(5xFAD-BZD-M)、高剂量组(5xFAD-BZD-H)及安理申
组(5xFAD-Donep)；同窝出生野生型小鼠随机分为正常对照组(WT-Control)、巴茱
合剂组(WT-BZD)、安理申组(WT-Donep)。每组小鼠 12 只。给药剂量为： 
5xFAD-BZD-L 组，5xFAD-BZD-M 组，5xFAD-BZD-M 组和 WT-BZD 组分别给
予巴茱合剂 4.225g/(kg·d)、8.450 g/(kg·d)、16.900 g/(kg·d)和 16.900 g/(kg·d)； 
5xFAD-Donep 组和 WT-Donep 组给予安理申 0.65mg/(kg·d)；5xFAD-Control 组和







关生物学标志物。与 Aβ 生成相关的 AD 机制是目前最受关注的研究焦点。神经
元胞外 β-淀粉样蛋白(Aβ)堆积是 AD 的经典病理表现之一。Aβ 的产生与否关系

























制研究发现，巴茱合剂对 5xFAD 小鼠脑组织中的 Aβ 斑块、β-分泌酶、γ-分泌酶、
AChE、MDA 的表达水平和 SOD 的活性都有影响(P＜0.05 或者 P＜0.01)。巴茱
合剂通过降低 β-分泌酶中的 BACE1、γ-分泌酶中的 PS1 等蛋白的表达，抑制 APP
的淀粉源水解途径，减轻 Aβ 的过度生成和聚集；以及通过抑制 AchE 表达、调
节 MDA/SOD 的异常水平和活性，进一步缓解 Aβ 淀粉样斑的沉积。 
结论：巴茱合剂提高 5xFAD 小鼠的学习记忆能力并改善其焦虑性过低的作
用机制可能是通过调节各种亚细胞水平蛋白进而抑制 β-淀粉样斑的生成。本文为


















Objective: Bazhu Decoction (BZD), originated from my master instructor’s 
experience, is an effective formulae of traditional Chinese medicine for Alzheimer's 
disease(AD). BZD has been proved effective on patients of AD in our group’s 
preliminary studies. However, the mechanism of BZD on AD remains unclear. 
Therefore, this study aimed to investigate whether BZD has positive therapy in AD 
transgenic mice and its molecular biological mechanisms. 
Method: (1) 5xFAD mice, a new kind of APP/PS1 transgenic mice, were 
selected in this study. 3-month-old 5xFAD mice were randomly divided into control 
group(5xFAD-Control), low-dose BZD group(5xFAD-BZD-L), middle-dose BZD 
group(5xFAD-BZD-M), high-dose BZD group(5xFAD-BZD-H) and Donepezil HCL 
group(5xFAD-Donep). Wild type littermates, were subjected to control group 
(WT-Control), BZD group(WT-BZD) and Donepezil HCL group(WT-Donep). There 
were 12 mice in each group. 5xFAD-BZD-L, 5xFAD-BZD-M, 5xFAD-BZD-M and 
WT-BZD mice were orally administrated with different dosages of BZD per day 
(4.225g/kg, 8.450 g/kg, 16.900 g/kg,16.900 g/kg). 5xFAD-Donep group and 
WT-Donep group were given 0.650mg/(kg·d) Donepezil HCL. 5xFAD-Control group 
and WT-Control group were treated with 20ml/(kg·d) ddH2O. All mice were 
administered once-daily gavage for 12 weeks. 
(2) Behavioral tests were used to observed the therapeutic effect of BZD on the 
cognitive and anxiety disorders of 5xFAD mice. The locomotor activity and 
anxiety-depression disorder of 5xFAD mice were estimated by open field test(OFT) 
and elevated plus maze(EPM). The spatial alternation ability, orientation learning 
memory and context-cued test capacity were detected via T/Y maze(T/YM), morris 
water maze(MWM) and cued and contextual fear conditioning test (CCFT).  
(3) Molecular biology methods were applied to explore the biomarkers 
associated with Aβ deposition. Recently, the mechanisms about β-amyloid protein(Aβ) 















classical pathologies in AD. Aβ proteins are generated from APP’s amyloidogenic 
pathway, which is participated by β-secretase and γ-secretase. Additionally, the 
hydrolysis methods of APP include neuroprotection non-amyloidogenic pathway that 
APP is sequentially cut by α-secretase and γ-secretase. Besides APP’s hydrolysis 
methods, the abnormal expressions of acetylcholinesterase (AChE) ,the increase of 
malondialdehyde (MDA) and the unusual activity of Superoxide Dismutase (SOD) 
also affect the formation of Aβ. Therefore, both APP, α-secretase, β-secretase, 
γ-secretase and AchE, MDA, SOD are improtant for the deposition of Aβ.  
Result: BZD has improved the cognitive and anxiety disorders on 5xFAD mice. 
6-month-old untreated 5xFAD mice have shown reduced anxiety in elevated plus 
maze, and memory loss in Y maze, cued and contextual fear conditioning test and 
morris water maze. The middle and high dosage of BZD have alleviated the low 
anxiety, improved the cognitive dysfunction of 5xFAD mice in behavioral tests(P＜
0.05 or P＜0.01). Furthermore, in the study of molecular biological mechanisms, I 
have found that BZD had regulated the content or activity of Aβ plaques, β-secretase, 
γ-secretase, AchE, MDA and SOD(P＜0.05 or P＜0.01). The Aβ deposition has been 
decreased by BZD via suppressing the protein expression in APP’s amyloidogenic 
pathway (BACE1 and PS1), the level of AchE and the balance of oxidative stress 
(MDA and SOD). 
Conclusion: In short, this paper has proved that BZD had regulated divers 
subcellular proteins’ levels to inhibit the generation of β-amyloid plaques on 5xFAD 
mice then improved their cognitive ability and low anxiety. The results of this study 
have provided BZD’s experimental basis for AD clinical treatments, and widened the 
ways of TCM strategy and application prospect in AD. 
Key Words: Bazhu Decoction; Alzheimer’s disease; 5xFAD transgenic mice; 
















摘 要 ..................................................................................................... I 
Abstract ............................................................................................... III 
目 录 .................................................................................................... V 
Catalog................................................................................................ VII 
缩略词中英文对照表 .......................................................................... IX 
第一章 前言 ......................................................................................... 1 
1.1 阿尔兹海默病...................................................................................................... 1 
1.1.1 阿尔兹海默病概述 ..................................................................................... 1 
1.1.2 阿尔兹海默病病理 ..................................................................................... 2 
1.1.3 阿尔兹海默病病因及发病机制 ................................................................ 4 
1.1.4 β-淀粉样蛋白的产生.................................................................................. 7 
1.2 中医药与阿尔兹海默病 ..................................................................................... 9 
1.2.1 中医药对 AD 的认识与治疗经验概述 .................................................... 9 
1.2.2 巴茱合剂治疗 AD 的前期基础............................................................... 10 
1.3 阿尔兹海默病的动物模型 ............................................................................... 12 
1.3.1 阿尔兹海默病动物模型概述 .................................................................. 12 
1.3.2 5xFAD 转基因小鼠 .................................................................................. 13 
1.4 本论文研究的内容与意义 ............................................................................... 14 
第二章 材料与方法 ........................................................................... 16 
2.1 实验材料和仪器设备 ....................................................................................... 16 
2.1.1 中药、西药、抗体和化学试剂 .............................................................. 16 
2.1.2 实验动物及给药方法 ............................................................................... 16 
2.1.3 主要试剂与溶液的配制 ........................................................................... 17 
2.1.4 主要实验仪器 ........................................................................................... 19 
2.2 实验方法 ............................................................................................................ 20 
2.2.1 中药和西药的制备 ................................................................................... 20 
2.2.2 小鼠基因型鉴定 ....................................................................................... 21 















2.2.4 免疫组化 .................................................................................................... 24 
2.2.5 蛋白免疫印记（western blot） ............................................................... 26 
2.2.6 丙二醛含量和超氧化物歧化酶活性检测.............................................. 28 
2.2.7 数据统计 .................................................................................................... 30 
第三章 实验结果及分析 .................................................................... 31 
3.1 5xFAD 小鼠基因型鉴定 .................................................................................. 31 
3.2 巴茱合剂提高 5xFAD 小鼠认知能力及改善焦虑性过低........................... 31 
3.2.1 巴茱合剂改善 5xFAD 小鼠焦虑性过低的精神障碍 ........................... 31 
3.2.2 巴茱合剂提高 5xFAD 小鼠学习记忆能力 ............................................ 33 
3.3 巴茱合剂降低 5xFAD 小鼠 β-淀粉样蛋白的沉积....................................... 38 
3.4 巴茱合剂对 5xFAD 小鼠 Aβ产生相关蛋白有影响 .................................... 41 
3.5 巴茱合剂对 5xFAD 小鼠胆碱能相关酶及氧化应激反应有影响 .............. 44 
第四章 讨论与展望 ........................................................................... 47 
4.1 巴茱合剂等中药治疗 AD的思路和前景 ...................................................... 47 
4.2 巴茱合剂影响 5xFAD 小鼠行为学的效果评价 ........................................... 48 
4.3 巴茱合剂干预 5xFAD 小鼠 Aβ生成相关机制的效果评价 ....................... 49 
4.4 实验小鼠选择及实验设计思路 ...................................................................... 51 
4.5 本实验的研究结论 ........................................................................................... 52 
4.6 本实验存在的不足和展望 ............................................................................... 52 
参考文献 ............................................................................................... 54 
致谢 ....................................................................................................... 61 

















Chinese abstract ..................................................................................... I 
Abstract ............................................................................................... III 
Chinese catalog...................................................................................... V 
Catalog................................................................................................ VII 
Acronym table in both Chinese and English ..................................... IX 
Chapter1  Introduction ........................................................................ 1 
1.1  Alzheimer's Disease ........................................................................................... 1 
1.1.1  Summary of alzheimer's disease ................................................................. 1 
1.1.2 Pathology of alzheimer's disease ................................................................ 2 
1.1.3 Etiologies and mechanisms of alzheimer's disease ................................... 4 
1.1.4 The formation of β-amyloid protein ........................................................... 7 
1.2 Traditional Chinese medicine and alzheimer's disease ................................ 9 
1.2.1 Recordation and therapeutic experiences of TCM in AD ......................... 9 
1.2.2 Preliminary basis of Ba Zhu Decoction for AD therapy  ....................... 10 
1.3 The animal model of alzheimer's disease ..................................................... 12 
1.3.1 Summary of alzheimer's disease animal model ....................................... 12 
1.3.2 5xFAD transgenic mice ............................................................................. 13 
1.4 Research content and significance ................................................................ 14 
Chapter2 Materials and Methods .................................................... 16 
2.1 Materials and equipments .............................................................................. 16 
2.1.1 BZD, Donepezil HCL, antibodies and chemical reagents ...................... 16 
2.1.2 Animals and treatments ............................................................................. 16 
2.1.3 The configuration of main reagents and solution .................................... 17 
2.1.4 Main experimental apparatuses ................................................................ 19 
2.2 Methods ............................................................................................................. 20 
2.2.1 The preparation of BZD and Donepezil HCL ......................................... 20 
2.2.2 Gene identification of mice ....................................................................... 21 
2.2.3 Behavioral tests .......................................................................................... 22 
2.2.4 Immunohistochemical ............................................................................... 24 















2.2.6 Detection of MDA content and SOD activity .......................................... 28 
2.2.7 Data statistics ............................................................................................. 30 
Chapter3 Results and Analysis ......................................................... 31 
3.1 Gene identification of 5xFAD mice ............................................................... 31 
3.2 BZD has improved the cognitive dysfunction and low anxiety on 5xFAD 
mice .............................................................................................................................. 31 
3.2.1 BZD has alleviated the low anxiety on 5xFAD mice .............................. 31 
3.2.2 BZD has enhanced the learning and memory ability on 5xFAD mice ... 33 
3.3 BZD has reduced the Aβ plaques on 5xFAD mice ...................................... 38 
3.4 BZD has effected the related proteins of Aβ deposition on 5xFAD mice 41 
3.5 BZD has effected the AchE, MDA and SOD on 5xFAD mice ................... 44 
Chapter4 Disscusion and Expectation ............................................. 47 
4.1 Prospects and thoughts about the treatment of TCM like BZD............... 47 
4.2 Evaluation of BZD on 5xFAD mice’s behavioral test ................................. 48 
4.3 Assessment of BZD on 5xFAD mice’s Aβrelated mechanism ................... 50 
4.4 Selection of laboratory mice and design of experiment ............................. 51 
4.5 The conclusion of this experiment ................................................................. 52 
4.6 Deficiencies and prospects of this experiment ............................................. 52 
References ............................................................................................ 54 
Acknowledgement ................................................................................ 61 
















英文缩写 英文全名 中文全名 
AD Alzheimer’s disease 阿尔兹海默病 
NFTs Neurofibrillar Tangles 神经纤维缠结 
Aβ β-amyloid protein β-淀粉样蛋白 
SP Senile Plaques 老年斑(淀粉样斑) 
APP β-amyloid precursor protein β-淀粉样前体蛋白 
FAD Familial AD 家族性 AD 
SAD Sporadic AD 散发性 AD 
LTP Long-term potentiation 长时程增强 
Ach Acetylcholine 乙酰胆碱 
CoA Acetyl Coenzyme A 乙酰辅酶 A 
ChAT Choline acetyltransferase 乙酰转移酶 
AChE Acetyl cholinesterase 乙酰胆碱酯酶 
AICD APP intracellular domain APP 胞内结构域 
ADAM A disintegrin and metalloproteinase 解聚素-金属蛋白酶 
BACE1 β-site APP cleaving enzyme 1 β-分泌酶 1 
PS(PS1/ PS2) Presenilins 早老素 
BZD Bazhu Decoction  巴茱合剂 
5xFAD five familial AD mutations 5个家族性基因突变 
Donep Donepezil HCL 盐酸多奈哌齐 
OFT Open Field Test 旷场实验 
EPM Elevated Plus Maze  高架十字迷宫 
T/YM T/Y Maze T/Y 迷宫 
MWM Morris Water Maze 水迷宫 
CCFT Cued and Contextual Fear conditioning Test 条件惊恐实验 
PVDF polyvinylidene fluoride 聚偏二氟乙烯膜 
MDA Malondialdehyde 丙二醛 






















早对 AD 进行报道的是德国医生 Alois Alzheimer。Alois 医生在 1901 年德国的




变，并在 1907 年作了详细报道。为了肯定 Alois 医生在神经和精神系统疾病方
面的卓越贡献，1910 年，他的同事，慕尼黑皇家精神病医院的院长 Kraepelin，





























管疾病和癌症，最终 AD 患者往往死于并发症。 
AD 是目前影响老年人生活质量和身心健康的常见疾病。随着人口老龄化趋
势加剧，人类寿命逐年增长，AD 发病率也迅速攀升，近 60 年里，AD 的发病率
已经增加了 4 倍。流行病学调查结果提示，AD 已成为发达国家的第四大死亡病
因，前三位为心脑血管疾病、癌症和中风，而中国的 AD 发病率几乎与发达国家
持平。高龄是 AD 发病的重要危险因素，根据《2014 年阿尔茨海默病事实与数
据》得知，AD 发病率在 65 到 69 岁之间为 3%，70 到 74 岁之间为 5%，75 到 79
岁之间为 8%，80 到 85 岁之间为 16%，整体呈指数增长，这说明只要人们寿命
够长，都免不了发生 AD。但是，在 90 岁以上超高龄人群中，研究者竟然发现
AD 发病率有所下降，因此，这又表明有些长寿的人可能终身不发生 AD[5]。据
有关数据调查显示，全球痴呆病人患病率达到 2.4 千万人，到 2050 年数据又将












中医药治疗 AD 便是其中具备较大潜力的途径之一，诸多 AD 相关的中医药临床
研究已取得了明显疗效，亟待更进一步挖掘和探索。 
1.1.2 阿尔兹海默病病理 















作出了具体描述，并于 1907 年发表公开报道。他通过对已故女病人 Auguste Deter
大脑组织的病理学检测，发现存在三大病理改变，即神经元丢失、胞内神经纤维
（Neurofibrillar Tangles，NFTs）缠结和胞外淀粉样斑（又称老年斑，Senile Plaques，
SP）沉积[10]。其中，由过度磷酸化的 Tau 蛋白导致的神经纤维缠结和 β-淀粉样
蛋白（β-amyloid protein，Aβ）组成的神经炎性斑块是目前学术界中，病理学家




图 1.1  AD 的两个重要病理学特征 
 Figure1.1  Two classical pathological features of AD   
(引自陈晔光等, 分子细胞生物学, 2006) 
神经炎性斑块即老年斑，位于神经元细胞外，约 50-200µm大小，它的核心
组成是一种含氨基酸微丝 40-43 个，直径 5-10nm 的不可溶的淀粉样物质，该淀
粉样物质因其 β-片层二级结构[11]而被命名为 Aβ 蛋白。Aβ 来源于 I 型跨膜蛋白 β
淀粉样蛋白前体蛋白（β-amyloid precursor protein, APP）的水解过程。虽然 APP
的水解过程有三种蛋白酶（α-分泌酶、β-分泌酶和 γ-分泌酶）参与，但是与 Aβ
产生具有直接关系的只有 β-分泌酶和 γ-分泌酶。APP 在上述两种酶的依次剪切
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